FARIA, A. G.; FARIA, ALINE GUIMARÃES DE.; FARIA, ALINE GUIMARÃES.; SOUZA, F. D.; DE SOUZA, FILIPE DIAS; ARAÚJO NETO, L. U.; UGULINO, L.; Leonardo Ugulino de Araújo Neto; http://lattes.cnpq.br/6150182151217479; http://lattes.cnpq.br/4230721117221276; http://lattes.cnpq.br/4018103089126917; FARIA, Aline Guimarães de.; SOUZA, Filipe Dias de.; BEZERRA, Isabel Maria de Araújo.; ARAÚJO NETO, Leonardo Ugulino de.
Resumo:
Increasing evidences points to serum TSH (Thyroid Stimulating Hormone) as an
independent predictor for diagnosis of thyroid carcinoma in patients with nodular
thyroid disease, but the mechanisms underlying this finding remain unexplained.
Currently is not clear if the TSH is involved in the development of thyroid cancer,
progression or both. This study aims to contribute for elucidation this issue. The main
objective is evaluate the correlation of TSH levels with the emergence of papillary
thyroid carcinoma, and if it is possible to estimate whether the use of this parameter as
a predictor of the emergence of this type of cancer. A retrospective analysis was
performed on patients’ pre-existing database from private histopathology clinic, in
Campina Grande - PB, in period from 2010 to 2012, who underwent diagnostic
investigation of thyroid nodules by fine needle aspiration (FNA) and/or biopsy and who
had serum TSH value before these procedures. We included patients with TSH levels
between 0.5 to 5.0 mg/dl, values which are not yet well established correlation with
papillary thyroid carcinoma, and exclude those with non-diagnostic sample in the
analysis of FNA. After analysis of 636 nodules, there was not found a relationship
between higher levels of TSH with occurrence of nodular malignant disease in the total
sample. However, this relationship was significant when analyzed only females
(p=0.03). The male sample did not show the same results, possibly because it does not
constitute a numerically significant sample, this fact may have influenced the total study
sample. Furthermore, we found a relationship between lower levels of TSH and benign
findings (Class II Bethesda) on FNA. Unable to establish a cutoff point from which we
have a greater risk malignancy in patients with nodular disease, but the relationship still
can not be denied. Future studies could address this point specifically.